Active substance
Results for the substance panitumumab
2 results
About this active substance
Panitumumab is a monoclonal antibody used in the treatment of metastatic colorectal cancer that expresses the epidermal growth factor receptor (EGFR). It works by blocking EGFR activity, thereby inhibiting tumor cell growth.
The medication is administered intravenously, as directed by a doctor, usually once every two weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as skin rashes, diarrhea, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include skin rashes, diarrhea, and fatigue. In rare cases, severe reactions such as dermatologic toxicity or anaphylactic reactions may occur. Patients should be informed of these risks before use.
The medication is administered intravenously, as directed by a doctor, usually once every two weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as skin rashes, diarrhea, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include skin rashes, diarrhea, and fatigue. In rare cases, severe reactions such as dermatologic toxicity or anaphylactic reactions may occur. Patients should be informed of these risks before use.